Drug Profile
Boserolimab - Merck Sharp & Dohme
Alternative Names: anti-cd27 agonist - Chinook Therapeutics; anti-CD27 antibody- Chinook Therapeutics; MK-5890Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BioNovion
- Developer Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD27 antigen stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 15 Jul 2021 Phase-II clinical trials in Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Hungary, Israel (IV) (NCT04924101)
- 28 Mar 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel (IV, Infusion)